Last Update: Oct 30, 2026 Understanding Drug Utilisation, Treatment Patterns, Clinical Outcomes, and Profile of the Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan for the Treatment of Metastatic Prostate Cancer: a Multicountry, AI-powered Registry (PULSE) ClinicalTrials.gov Identifier: [NCT07484269](https://clinicaltrials.gov/ct2/show/NCT07484269) Novartis Reference Number:CAAA617A02001 [See if you Pre-qualify](#trial-eligibility "See if you Pre-qualify") All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. ## Study Description The primary objective of the study is to describe real-world drug utilisation of lutetium (177Lu) vipivotide tetraxetan among patients with metastatic prostate cancer This study is planned as a multicountry, non-interventional, longitudinal AI-enhanced digital registry that will leverage advanced data extraction technologies to efficiently generate RWD. The primary objective of the study is to describe real-world drug utilisation of lutetium (177Lu) vipivotide tetraxetan among patients with metastatic prostate cancer. Condition Metastatic Prostate Cancer Overall Status Recruiting Number of Participants753 Start Date Sep 30, 2026 Completion Date Jul 31, 2031 Gender Male Age(s) - (Child, Adult, Older Adult) ## Eligibility Criteria Inclusion criteria: Age ≥ 18 years at index date \* Diagnosis of mPC \* PSMA positive \* Received at least one dose of lutetium (177Lu) vipivotide tetraxetan on or after mPC diagnosis date Exclusion criterion: • Current or prior participation in an investigational study within the 30-day period immediately prior to and including the index date, or within five half-lives of the investigational product (whichever is longer) Switzerland #### Novartis Investigative SIte Recruiting Basel,4056,Switzerland ## Worldwide Contacts If the location of your choosing does not feature any contact detail, please reach out using the information below. #### Novartis Pharmaceuticals Phone: [ +41613241111](tel:+41613241111) Email: